BioSpace News Archive

Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced the presentation of new data from the ongoing Phase 1 studies of SRF388 and SRF617.

LUMAKRAS Shows Median Overall Survival of 12.5 Months in Patients With Previously Treated Non-Small Cell Lung Cancer Data Confirms Rapid, Deep, and Durable Responses With Median Duration of Response of 11.1 Months Data Presented at ASCO 2021 and Simultaneously Published in New England Journal of Medicine

AmerisourceBergen Corporation (NYSE: ABC) today announced that it will participate virtually in the following upcoming investor conferences: Goldman Sachs 42nd Annual Global Healthcare Conference, to be held on June 8-11, 2021; and Baird Healthcare ESG Symposium, to be held on June 17, 2021.

Centessa Pharmaceuticals plc (“Centessa”), a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, announced today that, in connection with its previously announced initial public offering of 16,500,000 American Depositary Shares (“ADSs”).

Flexion Therapeutics, Inc. announced equity inducement grants to five new employees consisting of 8,510 restricted stock units.

European Biotech Acquisition Corp. (the “Company”) today announced it received a notice on May 28, 2021 from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that as a result of the Company’s failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2021 (the “Quarterly Report”), the Company no longer complies with the continued listing requirements set forth in Nasdaq Listing Rule 5250(c)(1).

Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, announced grants of stock options to six new employees to purchase an aggregate of 106,520 shares of the Company’s common stock with an exercise price of $4.03 per share, the closing price of Assembly Bio’s common stock on June 1, 2021.

Today, the U.S. Food and Drug Administration approved Ryplazim (plasminogen, human-tmvh) for the treatment of patients with plasminogen deficiency type 1, also referred to as hypoplasminogenemia, a disorder that can impair normal tissue and organ function and may lead to blindness.

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on June 2, 2021, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 30,375 shares of Puma common stock to five new non-executive employees.

Calgary-based biotechnology company launches on-site laboratory to provide rapid PCR COVID-19 testing with results within four hours: